Platform
Features
Pricing
0 followers
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.
Industries
Headquarters
Employees
Links
Full screen
Russell LaMontagne
View all (0)
This company has no teams yet
View all
HQ
0 positions, 0 job posts
Amgen
274 followers
Gilead Sciences
157 followers
Regeneron
124 followers
Illumina
78 followers
Agilent Technologies
Verily Life Sciences
45 followers
Alexion Pharmaceuticals
44 followers
GRAIL
27 followers
Cytiva
14 followers
PerkinElmer
11 followers
Editas Medicine
5 followers
Explore companies